How long can you live taking trametinib (survival period)?

Trametinib is an oral MEK inhibitor that is selective for MEK1 and MEK2 and is used alone or in combination with dabrafenib (Tafinlar) to treat certain types of melanoma, a type of skin cancer. It is also used in combination with dabrafenib to prevent certain types of melanoma from coming back after surgery. Trametinib is also used in combination with dabrafenib to treat certain types of non-small cell lung cancer (NSCLC) and thyroid cancer. It is also used in combination with dabrafenib to treat certain types of solid tumors in adults and children over 6 years old, and to treat certain types of glioma (a type of cancerous brain tumor) in children over 1 year old. Trametinib belongs to the kinase inhibitor class of drugs. It works by blocking the activity of an abnormal protein that sends a reproduction signal to cancer cells, which helps prevent the spread of cancer cells.

Trametinib is effective in treating cancer, delaying the progression of the disease and prolonging the survival of patients. Trametinib was more effective than the cancer drugs dacarbazine or paclitaxel at controlling melanoma that had spread to other parts of the body or could not be removed with surgery. Patients who took trametinib lived an average of 4.8 months before their disease worsened, compared with 1.5 months for those who took dacarbazine or paclitaxel. In a study involving 870 patients with surgically removed stage III melanoma, a combination of trametinib and dabrafenib given for 1 year was compared with placebo (dummy treatment). About 40% of patients who received the combination died or relapsed after an average of about 3.5 years, compared with 59% of patients who received a placebo. The above data show that trametinib combined with dabrafenib has a significant effect. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.